tradingkey.logo
tradingkey.logo
Search

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

ReutersSep 24, 2025 11:10 AM
facebooktwitterlinkedin
View all comments0

- FibroGen Inc FGEN.O:

  • FIBROGEN INITIATES PHASE 2 MONOTHERAPY TRIAL OF FG-3246, A FIRST-IN-CLASS CD46 TARGETING ADC, IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

  • FIBROGEN INC - INTERIM ANALYSIS OF TRIAL EXPECTED IN 2H 2026

  • FIBROGEN INC - TOPLINE RESULTS OF FG-3246 IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH MCRPC ENZALUTAMIDE EXPECTED Q4 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI